文献速递病毒性肝炎

血清HBsAg与HBcrAg动力学预测HBeAg阴性慢性乙型肝炎聚乙二醇干扰素治疗长期结局

Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy.
PubMed 文献 · Clin Microbiol Infect · 2017-07-24

该研究纳入121例HBeAg阴性慢性乙型肝炎患者,基于48周PEG-IFN单用或联合恩替卡韦的随机试验,系列检测HBsAg与HBcrAg并评估肝内cccDNA。治疗3年后持续病毒学应答率为29%(35/121),HBsAg清除率为9%(11/121)。基线高抗原水平及治疗12周抗原下降不足可高阴性预测持续应答与HBsAg清除。

要点

  • 基线HBcrAg与HBV DNA及cccDNA相关,但与HBsAg不相关。
  • 基线HBsAg≥3.4 log10 IU/mL且HBcrAg≥3.7 log10 U/mL对持续病毒学应答阴性预测值90%。
  • 治疗12周HBsAg与HBcrAg联合下降<0.5 log10对持续应答阴性预测值96%。

核心结论

  • 定量HBcrAg与HBeAg阴性CHB患者肝内cccDNA显著相关。
  • HBcrAg联合HBsAg可识别长期随访中持续病毒学应答和HBsAg清除概率低的患者。

研究设计与样本

  • 研究纳入121例来自既往48周PEG-IFN单用或联合恩替卡韦随机试验的泰国HBeAg阴性CHB患者。
  • 系列检测血清HBsAg与HBcrAg水平,并评估基线与治疗后配对肝活检的肝内cccDNA。

主要发现

  • 治疗3年后持续病毒学应答(HBV DNA<2000 IU/mL)率为29%(35/121),HBsAg清除率为9%(11/121)。
  • 基线HBcrAg与HBV DNA及cccDNA相关,但与HBsAg不相关。
  • 基线HBsAg及HBsAg与HBcrAg下降均与持续病毒学应答相关,HBsAg下降可预测HBsAg清除。
  • 基线HBsAg≥3.4 log10 IU/mL且HBcrAg≥3.7 log10 U/mL对持续病毒学应答阴性预测值为90%(45/50),对HBsAg清除阴性预测值为100%(50/50)。
  • 治疗12周HBsAg、HBcrAg及两者联合下降<0.5 log10对持续病毒学应答阴性预测值分别为90%(71/79)、82%(61/74)和96%(48/50)。

临床怎么用

  • 基线HBsAg与HBcrAg联合检测可用于识别PEG-IFN治疗后长期持续病毒学应答和HBsAg清除概率低的患者。
  • 治疗12周HBsAg与HBcrAg联合下降幅度可作为早期预测长期应答的指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the role of serum hepatitis B core-related antigen (HBcrAg) kinetics in predicting long-term outcome of pegylated interferon (PEG-IFN)-based therapy in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). METHODS: A total of 121 Thai patients with HBeAg-negative CHB recruited from a previous randomized trial of 48-week PEG-IFN alone or combined with entecavir were enrolled. Hepatitis B surface antigen (HBsAg) and HBcrAg levels were serially examined. Paired biopsy samples taken at baseline and after treatment were assessed for intrahepatic covalently closed circular DNA (cccDNA). RESULTS: Persistent virologic remission (PVR, defined by persistent hepatitis B virus (HBV) DNA <2000 IU/mL) and HBsAg clearance at 3 years after treatment were 29% (35/121) and 9% (11/121) respectively. Baseline HBcrAg correlated with HBV DNA and cccDNA but not with HBsAg. Baseline HBsAg, as well as HBsAg and HBcrAg, declines were associated with PVR, while HBsAg decline was predictive of HBsAg clearance. High baseline antigen levels (HBsAg ≥3.4 log10 IU/mL plus HBcrAg ≥3.7 log10 U/mL) yielded high negative predictive values of PVR (45/50, 90%) and HBsAg clearance (50/50, 100%). At week 12, declines of HBsAg, HBcrAg and both antigens combined of <0.5 log10 yielded negative predictive values for PVR of 90% (71/79), 82% (61/74) and 96% (48/50) respectively. CONCLUSIONS: Quantitative HBcrAg was significantly associated with cccDNA in HBeAg-negative CHB. This novel antigen, together with HBsAg, could identify patients with low probability of PVR and HBsAg clearance in long-term follow-up.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Chuaypen N, Posuwan N, Chittmittraprap S, et al. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy. Clin Microbiol Infect. 2017. PMID: 28750917. doi:10.1016/j.cmi.2017.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。